You have 9 free searches left this month | for more free features.

Capecitabine

Showing 1 - 25 of 2,086

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Colorectal Cancer, Colorectal Cancer Stage IV Trial (Fruquintinib Plus Capecitabine, Capecitabine)

Not yet recruiting
  • Colorectal Cancer
  • Colorectal Cancer Stage IV
  • Fruquintinib Plus Capecitabine
  • Capecitabine
  • (no location specified)
Jul 9, 2022

Recurrent Metastatic Nasopharyngeal Carcinoma Trial (Mitoxantrone HCl liposome injection, Capecitabine)

Not yet recruiting
  • Recurrent Metastatic Nasopharyngeal Carcinoma
  • Mitoxantrone hydrochloride liposome injection
  • Capecitabine
  • (no location specified)
Jan 29, 2023

Metastatic Colorectal Cancer Trial in Guangzhou (Fruquintinib alternating with Bevacizumab plus Capecitabine, Bevacizumab plus

Recruiting
  • Metastatic Colorectal Cancer
  • Fruquintinib alternating with Bevacizumab plus Capecitabine
  • Bevacizumab plus Capecitabine
  • Guangzhou, Guangdong, China
    Nanfang Hospital, Southern Medical University
Jan 4, 2023

Breast Tumors, Locally Advanced or Metastatic Breast Cancer Trial in Guangzhou (Taxane plus Intermittent Capecitabine, Utidelone

Not yet recruiting
  • Breast Neoplasms
  • Locally Advanced or Metastatic Breast Cancer
  • Taxane plus Intermittent Capecitabine
  • +3 more
  • Guangzhou, Guangdong, China
    Shusen Wang
Dec 27, 2021

Metastatic Pancreatic Adenocarcinoma Trial (Ivaltinostat, Capecitabine)

Not yet recruiting
  • Metastatic Pancreatic Adenocarcinoma
  • (no location specified)
Feb 10, 2022

Metastatic Colorectal Cancer Trial in Guangzhou (Cetuximab, Capecitabine)

Recruiting
  • Metastatic Colorectal Cancer
  • Guangzhou, Guangdong, China
    The Sixth Affiliated Hospital of Sun Yat-sen University
Mar 7, 2023

Metastatic HER2 Negative Breast Carcinoma, Brain Metastases, Capecitabine Trial in Changsha (UTD1 combined with capecitabine)

Recruiting
  • Metastatic HER2 Negative Breast Carcinoma
  • +3 more
  • UTD1 combined with capecitabine
  • Changsha, China
    Quchang Ouyang
Sep 9, 2022

Advanced Breast Cancer Trial (Dalpiciclib+ letrozole +capecitabine)

Not yet recruiting
  • Advanced Breast Cancer
  • Dalpiciclib+ letrozole +capecitabine
  • (no location specified)
Jul 21, 2022

Breast Cancer Trial in Beijing (oral vinorelbine and capecitabine)

Recruiting
  • Breast Cancer
  • oral vinorelbine and capecitabine
  • Beijing, Beijing, China
    National Cancer Center/National Clinical Research Center for Can
Feb 27, 2023

Nasopharyngeal Carcinoma Trial in Guangzhou (Sintilimab, Capecitabine)

Recruiting
  • Nasopharyngeal Carcinoma
  • Guangzhou, Guangdong, China
    Department of Nasopharyngeal Carcinoma, Sun Yat-sen University C
May 5, 2022

Pseudomyxoma Peritonei Trial in Milano (Capecitabine)

Recruiting
  • Pseudomyxoma Peritonei
  • Capecitabine
  • Milano, MI, Italy
    Fondazione IRCCS Istituto Nazionale dei Tumori di Milano
Apr 4, 2022

Hormone Receptor-positive Breast Cancer Trial in Tampa (Cemiplimab, Capecitabine)

Recruiting
  • Hormone Receptor-positive Breast Cancer
  • Tampa, Florida
    Moffitt Cancer Center
Jul 27, 2022

Cholangiocarcinoma, Intrahepatic Trial in Shanghai (Capecitabine, PD-1 Antibody(Tislelizumab))

Recruiting
  • Cholangiocarcinoma, Intrahepatic
  • Capecitabine
  • PD-1 Antibody(Tislelizumab)
  • Shanghai, China
    Lulu@Huashan.Org.Cn
Aug 16, 2022

Biliary Tract Cancer (CCA), Intrahepatic Cholangiocarcinoma, Hilar Cholangiocarcinoma Trial in Frankfurt am Main (Durvalumab,

Recruiting
  • Biliary Tract Cancer (CCA)
  • +4 more
  • Frankfurt am Main, Germany
    Krankenhaus Nordwest
Jun 23, 2022

Radiotherapy, PD-1 Inhibitor, Capecitabine Trial in Zhuhai (SBRT radiotherapy + Conventionally fractionated radiotherapy, PD-1

Recruiting
  • Radiotherapy
  • +3 more
  • SBRT radiotherapy + Conventionally fractionated radiotherapy
  • +2 more
  • Zhuhai, Guangdong, China
    Fifth Affilliated Hospital of Sun Yat-sen University
Apr 13, 2022

Metastatic Nasopharyngeal Carcinoma Trial (Capecitabine plus toripalimab)

Not yet recruiting
  • Metastatic Nasopharyngeal Carcinoma
  • Capecitabine plus toripalimab
  • (no location specified)
Jul 30, 2022

Metastatic Colorectal Cancer Trial in Beijing (fruquintinib plus capecitabine)

Recruiting
  • Metastatic Colorectal Cancer
  • fruquintinib plus capecitabine
  • Beijing, China
    National Center/Cancer Hospital, China Academy of Medical Scienc
Aug 17, 2022

Colorectal Cancer Metastatic, Peritoneal Carcinomatosis Trial in Amsterdam (Galunisertib plus capecitabine)

Not yet recruiting
  • Colorectal Cancer Metastatic
  • Peritoneal Carcinomatosis
  • Galunisertib plus capecitabine
  • Amsterdam, Netherlands
  • +1 more
Jan 17, 2023

Metastatic Colorectal Cancer Trial (Anti-PD-1 Monoclonal Antibody + Capecitabine)

Not yet recruiting
  • Metastatic Colorectal Cancer
  • Anti-PD-1 Monoclonal Antibody + Capecitabine
  • (no location specified)
Apr 30, 2022

Hand and Foot Syndrome, Erythrodysesthesia Syndrome, HFS Trial in Tanta (Celecoxib 200mg, Capecitabine-based chemo)

Recruiting
  • Hand and Foot Syndrome
  • +3 more
  • Celecoxib 200mg
  • Capecitabine-based chemotherapy
  • Tanta, Egypt
    Faculty of Pharmacy-Tanta University
Apr 7, 2022

Unresectable Metastatic Colorectal Cancer Trial in Beijing (fruquintinib plus capecitabine)

Recruiting
  • Unresectable Metastatic Colorectal Cancer
  • fruquintinib plus capecitabine
  • Beijing, China
    Beijing Friendship Hospital
Aug 17, 2022

Capecitabine Versus S-1 as Adjuvant Therapy in Biliary Tract

Recruiting
  • Biliary Tract Neoplasms
  • +3 more
  • Shanghai, China
    Huashan hospital
Aug 16, 2022

Gastroesophageal Junction Adenocarcinoma Trial in Shijiazhuang (Oxaliplatin; Capecitabine, Oxaliplatin; Capecitabine; concurrent

Completed
  • Gastroesophageal Junction Adenocarcinoma
  • Oxaliplatin; Capecitabine
  • Oxaliplatin; Capecitabine; concurrent radiotherapy
  • Shijiazhuang, Hebei, China
    Department of General Surgery
Feb 4, 2022

Breast Cancer Trial (Capecitabine and Neratinib.)

Not yet recruiting
  • Breast Cancer
  • Capecitabine and Neratinib.
  • (no location specified)
Jul 8, 2022